While recent medical discoveries, from drugs to imaging techniques, continue to revolutionize cancer care, none of them would be possible without foundations having been laid years, or even decades, earlier. Groundbreaking work by the late endocrinologist Jack Gorski, Ph.D., who passed away in 2006 and was funded by the National…...
Targeted Lung Cancer Therapy
A Match Made Possible A discovery by a team led by Massachusetts General Hospital’s Daniel Haber, M.D., Ph.D., a physician-scientist supported by the National Foundation for Cancer Research since 2003, now represents a source of hope for many patients with metastatic lung cancer. He and his colleagues correctly linked very…...
New Therapeutic Option for Triple-Negative Breast Cancer
Triple-negative breast cancer, one of the deadliest and most aggressive forms of breast cancer, spreads quickly, is resistant to many chemotherapies and is likely to reoccur even after a seemingly successful round of therapies. The cause for the later is the resiliency of a subset of cancer cells called cancer…...
Genetic Breakthrough in Aggressive Prostate Cancer Research
Cancer researchers at the Thomas Jefferson University in Philadelphia have zeroed in on a specific type of gene loss that sets off large-scale genetic changes that could make prostate cancer both resistant to treatment and more likely to spread. The discovery concerns the retinoblastoma (RB) susceptibility gene, the first “gatekeeper…...
Novel CAR-T Treatment Approved for Second Indication
In the past two months, the FDA has approved a revolutionary new form of immunotherapy, called chimeric antigen receptor (CAR) T cell therapy, for two blood cancers: B cell acute lymphoblastic leukemia (ALL) in August, 2017 and now on October 18th, for aggressive diffuse large B cell lymphoma (DLBCL), a…...
Improving the Delivery and Efficacy of Anti-Cancer Therapeutics
In honor of National Medical Laboratory Professional Week, we’d like to highlight a few of the many accomplishments of NFCR-funded scientist, Dr. Rakesh Jain. About Dr. Rakesh Jain Rakesh K. Jain, Ph.D., Andrew Werk Cook professor of tumor biology (radiation oncology) at Harvard Medical School and director of the Edwin…...
Understanding Adaptive Clinical Trials
Testing new treatments is key to successfully treating cancer. Unfortunately, the current model for conducting clinical trials — evaluating the effectiveness of therapies on human subjects — is inefficient, expensive and suffers from high failure rates. To overcome these challenges, the practice of adaptive trials is emerging and has become one…...
Nano-Particles Open New Window for Biological Imaging
“Quantum dots” that emit infrared light enable highly detailed images of internal body structures Researchers have found a way to make tiny particles, known as quantum dots, that can be injected into the body and emit short-wave infrared light, enabling a new way to capture detailed images of internal body…...
Strategic Media Partner
